PCN13 Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib in Patients With Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia (CML)
Abstract
Authors
X. Niu J. Hay
X. Niu J. Hay
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now